The FDA has cleared Motivista, a prescription digital therapeutic, as an adjunctive treatment for negative symptoms of schizophrenia in outpatient care. Click Therapeutics announced the clearance, adding a software-based option to the psychiatric treatment landscape.
Negative symptoms of schizophrenia are a challenging aspect of the disorder, and the new clearance offers a non-drug approach for patients already receiving care. The agency's decision was reported alongside other psychiatry news, including a separate request for public input on ibogaine drug development to help design future early-phase clinical trials.
The ibogaine solicitation signals continued regulatory interest in novel psychiatric treatments, though it remains an early-stage effort. No further details on Motivista's efficacy or prescribing requirements were included in the source.